Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prospecting whole cancer genomes

Nature Cancer volume 1, pages 273–275 (2020)Cite this article

A new suite of studies from the Pan Cancer Analysis of Whole Genomes (PCAWG) Consortium provides the most detailed resolution of cancer genomes to date, extending our knowledge of driver genes, mutational features, structural alterations and more. Kreisberg, Ideker, Mills and Meric-Bernstam discuss the foundational and translational insights gained from this project.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hoadley, K. A. et al. Cell 173, 291–304.e6 (2018).

    Article  CAS  Google Scholar 

  2. International Cancer Genome Consortium. et al. Nature 464, 993–998 (2010).

    Article  Google Scholar 

  3. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature 578, 82–93 (2020).

    Article  Google Scholar 

  4. Zhang, W. et al. Nat. Genet. 50, 613–620 (2018).

    Article  CAS  Google Scholar 

  5. Melton, C., Reuter, J. A., Spacek, D. V. & Snyder, M. Nat. Genet. 47, 710–716 (2015).

    Article  CAS  Google Scholar 

  6. Hofree, M. et al. Nat. Commun. 7, 12096 (2016).

    Article  CAS  Google Scholar 

  7. Reyna, M. A. et al. Nat. Commun. 11, 729 (2020).

    Article  CAS  Google Scholar 

  8. Rheinbay, E. et al. Nature 578, 102–111 (2020).

    Article  CAS  Google Scholar 

  9. Paczkowska, M. et al. Nat. Commun. 11, 735 (2020).

    Article  CAS  Google Scholar 

  10. Shuai, S., Gallinger, S. & Stein, L. Nat. Commun. 11, 734 (2020).

    Article  CAS  Google Scholar 

  11. Jiao, W. et al. Nat. Commun. 11, 728 (2020).

    Article  CAS  Google Scholar 

  12. Yakneen, S. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0360-3 (2020).

    Article  CAS  Google Scholar 

  13. Gerstung, M. et al. Nature 578, 122–128 (2020).

    Article  CAS  Google Scholar 

  14. PCAWG Transcriptome Core Group. Nature 578, 129–136 (2020).

    Article  CAS  Google Scholar 

  15. Lui, G. Y. L., Grandori, C. & Kemp, C. J. J. Clin. Pathol. 71, 957–962 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of California San Diego, La Jolla, CA, USA

    Jason F. Kreisberg & Trey Ideker

  2. UT MD Anderson Cancer Center, Houston, TX, USA

    Funda Meric-Bernstam

  3. Knight Cancer Institute Oregon Health and Sciences University, Portland, OR, USA

    Gordon Mills

Authors
  1. Jason F. Kreisberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trey Ideker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Funda Meric-Bernstam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gordon Mills
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Trey Ideker, Funda Meric-Bernstam or Gordon Mills.

Ethics declarations

Competing interests

G.B.M. is on the scientific advisory board or is a consultant for AstraZeneca, Chrysallis Biotechnology, ImmunoMET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen and Tarveda; has stock, options or other financial interests in Catena Pharmaceuticals, ImmunoMet, SignalChem and Tarveda; has a licensed technology HRD assay to Myriad Genetics, and DSP patents with Nanostring; has research sponsored by Nanostring Center of Excellence and Ionis (provision of tool compounds only). F.M.-B is on the scientific advisory board or is a consultant for Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology, Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Aduro BioTech, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche, Genentech, IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer, Samsung Bioepis, Seattle Genetics, Tyra Biosciences, Xencor and Zymeworks; has research sponsored by Aileron Therapeutics, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Curis Inc., CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Genentech, Guardant Health, Millennium Pharmaceuticals, Novartis, Puma Biotechnology and Taiho Pharmaceutical; and receives honoraria from Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey and UT Health San Antonio. T.I. is co-founder of and has an equity interest in Data4Cure; and has an equity interest in Ideaya BioSciences; the terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kreisberg, J.F., Ideker, T., Meric-Bernstam, F. et al. Prospecting whole cancer genomes. Nat Cancer 1, 273–275 (2020). https://doi.org/10.1038/s43018-020-0045-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-020-0045-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing